サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1722528

黄斑変性治療市場レポート：タイプ別、病期別、投与経路別、エンドユーザー別、地域別、2025年～2033年

Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 149 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.32円
黄斑変性治療市場レポート：タイプ別、病期別、投与経路別、エンドユーザー別、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

黄斑変性治療の世界市場規模は2024年に99億米ドルに達しました。今後、IMARC Groupは、2033年には158億米ドルに達し、2025～2033年の成長率（CAGR）は5.28％になると予測しています。市場は、特に新興経済諸国における、加齢黄斑変性や肥満の増加、座りがちなライフスタイルの普及、スマートデバイスの急速な活用、ヘルスケアインフラの大幅な改善などが主な要因となっています。

黄斑変性症は神経変性眼疾患であり、眼を侵し、視野の中心部のぼやけや視力低下を引き起こします。視野の盲点、視覚の歪み、暗い場所での見えにくさなどが特徴です。黄斑変性症の治療法としては、血管新生阻害薬、光線力学的レーザー治療、コンタクトレンズ、移行レンズなどが一般的に使用されています。レーザー治療では、眼球の患部に専用のコンタクトレンズを挿入し、血管とともにレーザーで密封します。血管新生阻害薬は、血管の閉塞や漏れを防ぐために使用されます。黄斑変性治療のタイムリーな治療は、視力を向上させ、慢性失明のリスクを最小限に抑えるのに役立ちます。

黄斑変性治療の市場動向：

加齢黄斑変性と肥満の増加が市場成長を促進する主な要因の一つです。食事パターンの変化や座りがちなライフスタイルの増加が、黄斑変性症の開発につながっています。さらに、スマートフォン、ノートパソコン、テレビの利用が増え、長時間、過度なスクリーンタイムを過ごすようになっていることも、この疾患の発生に影響を与えています。さらに、異常な血管の発達を防ぐためにアデノ随伴ウイルス（AAV）を体内に注入する網膜遺伝子治療の開発が、市場の成長を後押ししています。これに伴い、ヘルスケアインフラの大幅な改善が市場成長にプラスの影響を与えています。その他の要因としては、革新的で効果的な薬剤の開発のための広範な研究開発（R&D）活動や、公衆衛生を促進するための様々な政府イニシアチブの実施などが挙げられ、市場の成長を後押しすると予想されます。

本レポートで扱う主な質問

  • 2024年の世界の黄斑変性治療市場規模は？
  • 2025年～2033年の黄斑変性治療世界市場の予測成長率は？
  • 黄斑変性治療の世界市場を牽引する主要因は？
  • 黄斑変性治療の世界市場におけるCOVID-19の影響は？
  • 黄斑変性治療の世界市場におけるタイプ別の区分は？
  • 黄斑変性治療の世界市場における病期別の区分は？
  • 黄斑変性治療の世界市場における投与経路別の区分は？
  • 黄斑変性治療の世界市場におけるエンドユーザー別の区分は？
  • 黄斑変性治療の世界市場における主要地域は？
  • 黄斑変性治療の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の黄斑変性治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 萎縮型加齢黄斑変性
  • 滲出型加齢黄斑変性

第7章 市場内訳：病期別

  • 早期
  • 中期
  • 後期

第8章 市場内訳：投与経路別

  • 静脈内投与
  • 硝子体内経路

第9章 市場内訳：エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Aerie Pharmaceuticals Inc.
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche Ltd
    • Iveric Bio Inc.
    • Novartis AG
    • Panoptica
    • Pfizer Inc.
    • Phio Pharmaceuticals
    • Regeneron Pharmaceuticals Inc.
    • Regenxbio Inc.
    • Santen Pharmaceutical Co. Ltd.
図表

List of Figures

  • Figure 1: Global: Macular Degeneration Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Macular Degeneration Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Macular Degeneration Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Macular Degeneration Treatment Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Macular Degeneration Treatment Market: Breakup by Stage of Disease (in %), 2024
  • Figure 6: Global: Macular Degeneration Treatment Market: Breakup by Route of Administration (in %), 2024
  • Figure 7: Global: Macular Degeneration Treatment Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Macular Degeneration Treatment Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Macular Degeneration Treatment (Early Stage) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Macular Degeneration Treatment (Early Stage) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Macular Degeneration Treatment (Intermediate Stage) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Macular Degeneration Treatment (Intermediate Stage) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Macular Degeneration Treatment (Late Stage) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Macular Degeneration Treatment (Late Stage) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Macular Degeneration Treatment (Intravenous Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Macular Degeneration Treatment (Intravenous Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Macular Degeneration Treatment (Intravitreal Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Macular Degeneration Treatment (Intravitreal Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Macular Degeneration Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Macular Degeneration Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Macular Degeneration Treatment (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Macular Degeneration Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia-Pacific: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia-Pacific: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Macular Degeneration Treatment Market: Breakup by Country (in %), 2024
  • Figure 77: Middle East and Africa: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Global: Macular Degeneration Treatment Industry: SWOT Analysis
  • Figure 79: Global: Macular Degeneration Treatment Industry: Value Chain Analysis
  • Figure 80: Global: Macular Degeneration Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Macular Degeneration Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Macular Degeneration Treatment Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Macular Degeneration Treatment Market Forecast: Breakup by Stage of Disease (in Million USD), 2025-2033
  • Table 4: Global: Macular Degeneration Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Macular Degeneration Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Macular Degeneration Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Macular Degeneration Treatment Market: Competitive Structure
  • Table 8: Global: Macular Degeneration Treatment Market: Key Players
目次
Product Code: SR112025A5118

The global macular degeneration treatment market size reached USD 9.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.8 Billion by 2033, exhibiting a growth rate (CAGR) of 5.28% during 2025-2033. The market is majorly driven by the increasing incidences of age-related macular degeneration and obesity among the masses, growing prevalence of sedentary lifestyles, rapid utilization of smart devices, and significant improvements in the healthcare infrastructure, particularly in developing economies.

Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.

Macular Degeneration Treatment Market Trends:

The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Type:

  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration

Breakup by Stage of Disease:

  • Early Stage
  • Intermediate Stage
  • Late Stage

Breakup by Route of Administration:

  • Intravenous Route
  • Intravitreal Route

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Center
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.

Key Questions Answered in This Report

  • 1.What was the size of the global macular degeneration treatment market in 2024?
  • 2.What is the expected growth rate of the global macular degeneration treatment market during 2025-2033?
  • 3.What are the key factors driving the global macular degeneration treatment market?
  • 4.What has been the impact of COVID-19 on the global macular degeneration treatment market?
  • 5.What is the breakup of the global macular degeneration treatment market based on the type?
  • 6.What is the breakup of the global macular degeneration treatment market based on the stage of disease?
  • 7.What is the breakup of the global macular degeneration treatment market based on the route of administration?
  • 8.What is the breakup of the global macular degeneration treatment market based on the end user?
  • 9.What are the key regions in the global macular degeneration treatment market?
  • 10.Who are the key players/companies in the global macular degeneration treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Macular Degeneration Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Dry Age-related Macular Degeneration
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Wet Age-related Macular Degeneration
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Stage of Disease

  • 7.1 Early Stage
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intermediate Stage
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Late Stage
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Intravenous Route
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intravitreal Route
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Center
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Aerie Pharmaceuticals Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Bausch Health Companies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bayer AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Iveric Bio Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Novartis AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Panoptica
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Phio Pharmaceuticals
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Regeneron Pharmaceuticals Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Regenxbio Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Santen Pharmaceutical Co. Ltd.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis